Jim Simons Grifols Sa Transaction History

Renaissance Technologies LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 13, 2021	SELL	$15.15 - $19.78 $6.62 Million - $8.65 Million	-437,187 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$16.86 - $19.67 $810,359 - $945,418	48,064 Added 12.35%	437,187 $8.06 Million
Q3 2020 Nov 13, 2020	BUY	$15.4 - $20.16 $4.82 Million - $6.31 Million	313,016 Added 411.28%	389,123 $6.75 Million
Q2 2020 Aug 13, 2020	SELL	$18.24 - $21.45 $4.5 Million - $5.3 Million	-246,928 Reduced 76.44%	76,107 $1.39 Million
Q1 2020 May 14, 2020	SELL	$16.28 - $25.63 $2.73 Million - $4.29 Million	-167,536 Reduced 34.15%	323,035 $6.51 Million

Q4 2019 Feb 13, 2020	SELL	$19.57 - $23.52 $3.46 Million - $4.16 Million	-176,816 Reduced 26.49%	490,571 $11.4 Million
Q3 2019 Nov 13, 2019	BUY	$19.85 - $22.76 $9.73 Million - $11.2 Million	490,283 Added 276.83%	667,387 $13.4 Million
Q2 2019 Aug 12, 2019	SELL	$17.59 - $21.1 $1.89 Million - $2.27 Million	-107,600 Reduced 37.79%	177,104 $3.74 Million
Q1 2019 May 14, 2019	BUY	$18.01 - $20.11 $2.54 Million - $2.83 Million	140,900 Added 97.98%	284,704 $5.73 Million
Q4 2018 Feb 13, 2019	BUY	$17.44 - $21.53 $2.51 Million - $3.1 Million	143,804 New	143,804 $2.64 Million

150

140M

3.54M

919K

Ticker GRFS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 678,910,976
Market Cap $4.43B
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.